Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Andrew J. Aguirre, Brian M. Wolpin et al.|Cancer Discovery|2024Cited by 234
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Clinical Cancer Research|2024Cited by 42
Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBCLaura M. Spring, Leif W. Ellisen, Bogang Wu et al.|Cancer Research|2024Cited by 2
Supplementary Figure 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0
Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0